MCRS1 is essential for epiblast development during early mouse embryogenesis

Wei Cui^{1,2}, Agnes Cheong¹, Yongsheng Wang³, Yuran Tsuchida¹, Yong Liu⁴,
Kimberly D Tremblay¹ and Jesse Mager¹

¹Department of Veterinary and Animal Sciences, University of Massachusetts, Amherst, Massachusetts, USA,

²Animal Models Core Facility, Institute for Applied Life Sciences (IALS), University of Massachusetts, Amherst, Massachusetts, USA, ³Key Laboratory of Animal Biotechnology of the Ministry of Agriculture, College of Veterinary Medicine, Northwest A&F University, Yangling, Shaanxi, People's Republic of China and ⁴Anhui Province Key Laboratory of Embryo Development and Reproductive Regulation, Anhui Province Key Laboratory of Environmental Hormone and Reproduction, Fuyang Normal University, Fuyang, Anhui, People's Republic of China

Correspondence should be addressed to W Cui or J Mager; Email: wcui@umass.edu or jmager@vasci.umass.edu

Abstract

Microspherule protein 1 (MCRS1, also known as MSP58) is an evolutionarily conserved protein that has been implicated in various biological processes. Although a variety of functions have been attributed to MCRS1 *in vitro*, mammalian MCRS1 has not been studied *in vivo*. Here we report that MCRS1 is essential during early murine development. *Mcrs1* mutant embryos exhibit normal morphology at the blastocyst stage but cannot be recovered at gastrulation, suggesting an implantation failure. Outgrowth (OG) assays reveal that mutant blastocysts do not form a typical inner cell mass (ICM) colony, the source of embryonic stem cells (ESCs). Surprisingly, cell death and histone H4 acetylation analysis reveal that apoptosis and global H4 acetylation are normal in mutant blastocysts. However, analysis of lineage specification reveals that while the trophoblast and primitive endoderm are properly specified, the epiblast lineage is compromised and exhibits a severe reduction in cell number. In summary, our study demonstrates the indispensable role of MCRS1 in epiblast development during early mammalian embryogenesis.

Reproduction (2020) **159** 1–13

Introduction

Mammalian preimplantation embryo development begins with oocyte fertilization and concludes with the formation of a blastocyst-stage embryo that is capable of uterine implantation (Arny *et al.* 1987). During this period, the newly formed embryo undergoes three major transcriptional and morphogenic events. The first event, maternal-to-zygotic transition (MZT), initiates the epigenetic reprogramming that is required to establish totipotency (Latham *et al.* 1991, Liu *et al.* 2018). Following several early cleavage divisions, the eight-cell embryo initiates compaction and polarization, events critical for the first cell-fate acquisition (Sutherland & Calarco-Gillam 1983, Houlston & Maro 1989). The last major preimplantation event occurs when the polarized outer cells of compacted morula differentiate into the trophectoderm (TE) of the blastocyst, while the apolar cells located inside develop into the inner cell mass (ICM) (Nichols *et al.* 1998, Tompers *et al.* 2005). Well-defined gene expression profiles occur within these two distinct lineages to maintain and reinforce cell fate. For example, the transcription factor (TF) CDX2 is enriched in TE, whereas the TF OCT4 (alias POU5F1) becomes

highly expressed in the ICM (Niwa *et al.* 2005). At approximately the 32 cell stage, the ICM becomes segregated into epiblast (EPI) and primitive endoderm (PE), demarcated by NANOG expression in the EPI cells and SOX17 in the PE (Strumpf *et al.* 2005). These first three lineages EPI, PE, and TE will give rise to the embryo, parietal yolk sac, and placenta, respectively.

Lineage specification during early embryogenesis is a highly regulated process that relies on the differential expression of various genes within distinct cell populations. In addition to key TFs, such as NANOG and CDX2, many additional genes required for specific lineage function have been identified through large-scale RNAi screening and genome editing (Cao *et al.* 2015, Cui *et al.* 2016, 2018). By using an advanced single-cell gene-expression and 3D mapping analysis, microspherule protein 1 (MCRS1) was recently identified as a putative EPI-specific marker in human blastocysts (Durruthy-Durruthy *et al.* 2016). Remarkably, overexpression of MCRS1 as well as two other novel EPI markers TET1 and THAP11, leads to the resetting of primed human embryonic stem cells (hESCs) to naive pluripotency *in vitro* (Durruthy-Durruthy *et al.* 2016).

The role of MCRS1 has not yet been assessed during human development due to limitations of working with human embryos.

MCRS1 (also called MSP58 or P78) is an evolutionarily conserved protein that was initially identified in yeast as a nucleolar protein associated with rRNA transcription and cell proliferation (Ren *et al.* 1998). Later in both yeast and humans, MCRS1 was found to act as the regulatory component of the chromatin remodeling INO80 complex, catalyzing ATP-dependent sliding of nucleosomes along DNA (Jin *et al.* 2005). In both *Drosophila* and human, MCRS1 is a subunit of the non-specific lethal (NSL) Complex, which can acetylate nucleosomal histone H4 on multiple lysine residues, including lysine 5 (H4K5), 8 (H4K8), and 16 (H4K16) (Cai *et al.* 2010). Interestingly, in *Drosophila*, MCRS1 promotes gene transcription by facilitating the recruitment of the RNA polymerase II (RNAP II) preinitiation complexes to the promoter regions of target genes (Andersen *et al.* 2010). In human cell lines, MCRS1 has also been implicated in proliferation, inducing senescence, mitotic spindle assembly, activation of mechanistic target of rapamycin complex 1 (mTORC1), and tumorigenesis (Benavides *et al.* 2013, Liu *et al.* 2014, Fawal *et al.* 2015). However, the function of MCRS1 during mammalian development has not been studied.

In the present study, we use both knockout (KO) and knockdown (KD) strategies to explore the role of MCRS1 during murine development. Our data show that MCRS1 is essential for early embryo survival and successful implantation due to a specific role in epiblast function and development during the initial stages of lineage commitment and expansion.

Materials and methods

Unless otherwise specified, all chemicals and media were obtained from Millipore-Sigma.

Generation of *Mcrs1* mutants

All animal experimental protocols were approved by the Institutional Animal Care and Use Committee of the University of Massachusetts, Amherst (2015-0011, 2018-0003). *Mcrs1* KO allele (B6N(Cg)-*Mcrs1*^{tm1.1(KOMP)Vlcg/J}, Stock#: 025386) was generated on C57BL/6NJ background by the Knockout Mouse Phenotyping Program (KOMP2) at The Jackson Laboratory (JAX). Briefly, a beta-galactosidase containing ZEN-UB1 Velocigene cassette (Cassette#: VG16025) was inserted into the *Mcrs1* gene, replacing all coding exons and intervening sequences (Fig. 1A) and creating a deletion of 7372 bp between positions 99,250,469 – 99,243,098 of Chromosome 15 (Genome Build 38). The construct was introduced into C57BL/6N-derived VGB6 embryonic stem cells and the resulting chimeric males bred to C57BL/6NJ females. Offspring were crossed to B6N.Cg-Tg(Sox2-cre)1Amc/J to remove the neo cassette and the offspring were crossed

to remove the transgene. To expand the line in our colony, heterozygous (Het) mice from JAX were backcrossed again with C57BL/6NJ WT. Heterozygous intercrosses were used to generate *Mcrs1* mutants (Mut). The genotyping primers include WT Forward: CCCTGACTTGGGTCAGAGTT; WT Reverse: CTGCATCTGAGAAGTTGAGCA; Mut Forward: CCGTCGCTACCATTACCAGT; Mut Reverse: CTTGCCTCAAA GGCTCAATC.

Embryo recovery, culture and genotyping

For natural matings, *Mcrs1* heterozygous females 8 to 14 weeks old were caged with *Mcrs1* heterozygous males and the presence of a vaginal plug defined as embryonic day 0.5 (E0.5). Embryos were collected from heterozygous females by dissection or flushing to collect E7.5 or E3.5 embryos, respectively. Embryos were imaged, collected into individual tubes and then lysed for PCR genotyping.

To prepare zygotes for siRNA microinjection or *in vitro* culture and immunofluorescence, B6D2F1 female mice 8 to 10 weeks old were super-ovulated with 7.5 IU pregnant mare serum gonadotropin (PMSG, BioVendor, Asheville, NC, USA), followed 48 h later by 7.5 IU human chorionic gonadotropin (hCG). Females were then mated with B6D2F1 males and euthanized 20 h post hCG injection. Zygotes were released from oviducts and cumulus cells were removed by pipetting in M2 medium containing hyaluronidase. Zygotes were washed in M2 and cultured in KSOM at 37°C in a humidified atmosphere of 5% CO₂, 5% O₂ balanced in N₂.

Outgrowth assay

Blastocysts were harvested and cultured individually in a single well of DMEM (Lonza, Allendale, NJ, USA) containing 10% fetal bovine serum (Atlanta Biologicals, Flowery Branch, GA, USA) and 1X GlutaMAX (Thermo Fisher Scientific). Blastocysts were allowed to attach and outgrow for 3 days at 37°C in a humidified atmosphere of 5% CO₂ prior to imaging and genotyping. Outgrowths were evaluated by morphology as previously demonstrated (Cui *et al.* 2016, 2018). Briefly, an outgrowth that displayed a distinctive ICM colony surrounded by trophoblast monolayer is considered a normal successful outgrowth, while outgrowths that fail to hatch, lack ICM colony or lack trophoblast monolayer are considered as failed outgrowths.

Immunofluorescence and imaging of preimplantation embryos

Immunofluorescence (IF) was performed as previously described (Cui *et al.* 2018). E3.5 blastocysts were freshly harvested by flushing and then cultured overnight at 37°C in a humidified atmosphere of 5% CO₂, 5% O₂ balanced in N₂ prior to fixation and IF (to ensure embryos had undergone EPI/PE/TE specification). *In vitro*-produced blastocysts were harvested at 4 days post microinjection. All primary antibodies for IF were used at 1:200 including mouse anti-CDX2 (BioGenex, MU392A-UC); rabbit anti-NANOG (Abcam, ab80892); rabbit anti-TRP53 (Cell Signaling Technology, #9284); rabbit

Figure 1 (A) Schematic of *Mcrs1* knockout allele generation. *lacZ*, β -galactosidase coding sequence from the *E. coli lacZ* gene; p(A), polyadenylation signal. (B) Representative genotyped embryos at E7.5. (C) Representative genotyped embryos at E3.5. (D) Outgrowths from WT and Het displayed a distinctive ICM (red dashed line) surrounded by trophoblast (blue dashed line), while Mut outgrowths did not display an ICM. Scale bars, 100 μ m.

anti-MCRS1 (Sigma-Aldrich, HPA039057); rabbit anti-H4K5+K8+K12+K16 (Abcam, ab177790); goat anti-SOX17 (R&D Systems, AF1924); goat anti-OCT4 (Abcam, ab27985). After suitable secondary antibody (Alexa Fluor, Thermo Fisher Scientific) and DAPI staining, embryos were individually transferred into single wells of a chambered slide (Corning Co., Corning) for imaging using a Nikon A1 Spectral Detector Confocal with FLIM Module. Z-stacks (20 $\times$ objective, 8 μ m sections) were collected and maximum projection applied. Embryos were handled individually such that each one was imaged and then recovered for PCR genotyping (example of individual blastocysts post imaging and genotyping shown in Supplementary Fig. 1, see section on [supplementary materials](#) given at the end of this article). Fluorescence intensity of H4 acetylation was quantified and analyzed as previously described (An *et al.* 2019). Briefly, high-resolution z-stack

images were acquired under identical capture settings, and relative intensities were measured on the raw images using ImageJ software (Schneider *et al.* 2012), with DAPI or OCT4 intensity as the reference.

X-gal (5-bromo-4-chloro-3-indolyl- β -D-galactopyranoside) staining

Freshly dissected embryos were fixed in X-gal buffer containing 0.2% glutaraldehyde and 1% formaldehyde on ice for 15 min and subjected to modifications from previous protocol (Tremblay *et al.* 2000). In brief, the fixed embryos were washed with X-gal buffer (PBS, 5 mM EGTA, 2 mM MgCl $_2$ ·6H $_2$ O, 0.2% NP-40, 0.2 mM deoxycholate) for 10 min three times and stained with X-gal stain (X-gal buffer with 5 mM potassium ferricyanide, 5 mM potassium ferrocyanide,

and 0.5 mg/ml X-gal) for 48 h at 37°C. Subsequently, embryos were dehydrated in ethanol, cleared in xylene, embedded in paraffin, and sectioned at 7 µm. Slides were deparaffinated in xylene, counterstained with Eosin and coverslipped in Cytoseal (Thermo Fisher Scientific) and imaged with a Panoramic MIDI II slide scanner (3DHISTECH Ltd., Budapest, Hungary).

Microinjection

Microinjection was performed as previously described (Cui *et al.* 2016). A volume of 5–10 pL of 50 µM Scrambled Control (5'-CAGGGTATCGACGATTACAAA, Qiagen) or *Mcrs1* siRNA (siRNA1 target: 5'-CAAGGTGTCATCAAGTTGAAA, siRNA2 target: 5'-CTCAAGGACATGCGAGATGAA, Qiagen) was microinjected into the cytoplasm of zygotes.

RNA extraction and reverse transcription PCR (RT-PCR)

Total RNA extraction was performed with a Roche High Pure RNA Isolation Kit (#11828665001). cDNA was synthesized using iScript cDNA synthesis kit (#170-8891; Bio-Rad Laboratories). Intron-spanning primers used for RT-PCR include (*Actb*: 5'-GGCCCAGAGCAAGAGAGGTATCC and 5'-ACGCACGATTCCCTCTCAGC; *Mcrs1*: 5'-GAGCCCTCC TCTAGTGAGAAG and 5'-ACCCAGGTGGACAGATGTCA).

Statistical analysis

All experiments were repeated at least three times. Percentage data were analyzed by ANOVA, and a value of $P < 0.05$ was considered statistically significant. Data are expressed as mean $\pm$ S.E.M.

Results

Mcrs1 mutants cannot be recovered in vivo after E3.5

The *Mcrs1* knockout allele was generated by insertion of ZEN-UB1 Velocigene cassette (Cassette#: VG16025, <http://velocigene.com/komp/detail/16025>) for the Knockout Mouse Phenotyping Program (KOMP2) at The Jackson Laboratory (Fig. 1A). During the initial phenotyping performed for the International Mouse Phenotyping Consortium (IMPC), no homozygous *Mcrs1* mutants were born, nor found at E15.5 or E12.5 (<http://www.mousephenotype.org>). Therefore, we first dissected embryos at E7.5. Forty embryos were recovered from seven heterozygous intercrosses. Genotyping revealed 25 Het and 15 WT embryos (Fig. 1B). No *Mcrs1* homozygous mutant embryos were present at E7.5, nor were there increased numbers of empty decida ($n=4$), suggesting that *Mcrs1* mutants fail to implant. We next collected three litters of embryos at E3.5, and recovered four *Mcrs1* mutants, ten Het and two WT embryos at the blastocyst stage. Mutant blastocysts were indistinguishable from littermates based on morphology alone (Fig. 1C).

Since *Mcrs1* mutant blastocysts appear morphologically normal but are not found at E7.5,

we performed *in vitro* outgrowth assays as a surrogate for implantation *in vivo* which allows for assessment of hatching from the zona pellucida as well as ICM and TE cell growth. Blastocysts were obtained from three heterozygous intercrosses and individual embryos were cultured for 3 days on tissue culture plastic. As expected, hatching and successful outgrowth rates were high for WT (100%, 3/3) and Het blastocysts (80%, 8/10). By 72 h in culture, successful outgrowths display a distinct 3D ICM colony surrounded by trophoblast cells which are easily identified by their flattened morphology (Fig. 1D). Although each mutant blastocyst hatched and produced trophoblast and primitive endoderm cells, none of the four mutants assayed formed a typical ICM colony. These results suggest that the implantation failure of *Mcrs1* mutant blastocysts is due to impaired signaling from or proliferation of the ICM.

Expression of MCRS1 during early mouse embryogenesis

Based on the phenotype and timing of lethality, we evaluated MCRS1 expression during preimplantation and gastrulation stages. Immunofluorescence (IF) and RT-PCR analysis of WT preimplantation embryos revealed that *Mcrs1* mRNA and protein are present at all stages examined (Fig. 2A and B). MCRS1 protein is present in both the cytoplasm and nucleus from the oocyte through the two-cell stage. By the four-cell stage, MCRS1 appears more concentrated in the nucleus and by the blastocyst stage MCRS1 becomes notably concentrated in the nuclei of ICM cells compared with the TE (Fig. 2A). In order to validate the antibody, we performed IF on late blastocysts (dissected at E3.5 and cultured overnight to further deplete the maternally loaded protein/mRNA) from Het intercrosses. Each embryo was genotyped after imaging to retrospectively examine the images knowing specific genotypes. MCRS1 protein was observed in both ICM and TE from all WT ($n=6$) and Het ($n=10$) blastocysts (possible enriched in the ICM). However, no signal was detected in ICM nor TE of any mutant embryos ($n=5$, Fig. 2C). All embryos regardless of genotype showed non-specific signal on the zona pellucida. Based on the absence of antibody signal specifically in mutant embryos, these results confirm that the knockout allele does not produce MCRS1 protein.

We also examined MCRS1 expression during gastrulation by examining expression of the LacZ reporter, inserted during generation of the knockout allele, in Hets. At E6.5, LacZ is weak but present throughout cells of the epiblast (Epi) and extra-embryonic ectoderm (Exe) cells (Fig. 2D and D') but is largely absent from the visceral endoderm (VE). At E7.5, this same lineage-specific pattern continues (Fig. 2D and D"). Together, the LacZ-staining pattern observed during gastrulation is consistent with the ICM enriched expression observed in blastocysts (Fig. 2A).

Figure 2 (A) Immunofluorescence (IF) identifying MCRS1 protein expression from the metaphase II oocyte to the blastocyst stage. Scale bar, 50 μ m. (B) RT-PCR to identify *Mcrs1* expression in WT pre-implantation embryos. *Actb* was used as loading control. Oo, metaphase II oocyte; Zy, zygote; 2C, 2-cell embryo; 4/8C, mix of 4- and 8-cell stage embryos; Mo, morula; Blas, Blastocyst. (C) WT and Het blastocysts express MCRS1 protein in both ICM and TE, while no signal is detected in homozygous mutants (all embryos show non-specific zona staining). Scale bar, 50 μ m. (D) LacZ-reporter staining of both E6.5 and E7.5 Hets. Exe, extra-embryonic ectoderm; Epi, epiblast; VE, visceral endoderm. Ec, ectoderm; Me, mesoderm; En, endoderm. D' and D'': enlarged LacZ staining showing that LacZ is present throughout cells of the Epi and Exe cells but is largely absent from the VE.

Mcrs1 mutants have fewer ICM cells

To explore the mechanism of embryonic lethality *in vivo* and outgrowth failure *in vitro*, we first examined markers of apoptosis (active TRP53) and the first cell lineage specification (OCT4 for ICM and CDX2 for TE). Of 20

blastocysts examined from heterozygous intercrosses (4 WT, 12 Het, 4 Mut), none showed appreciable levels of active TRP53, indicating no increase in cell death in *Mcrs1* mutant blastocysts (Fig. 3A and Supplementary Fig. 2). All embryos exhibited OCT4 expression specifically

in the ICM and mutually exclusive CDX2 expression in the TE. Although OCT4 expression was confined to a cluster of cells within *Mcrs1*^{-/-} blastocysts, there is an obvious reduction in the number of OCT4-positive cells compared with Het and WT littermates (Fig. 3A). Further

quantification of several litters of embryos demonstrated that although blastocysts of all genotypes (9 WT, 26 Het, 10 Mut) have a similar total cell number (Fig. 3B), the percentage of OCT4-positive cells is severely reduced in mutant blastocysts (Fig. 3C). Concordant with reduced

Figure 3 (A) IF of OCT4 (ICM marker), CDX2 (TE marker), and active TRP53 (apoptosis marker) in blastocysts of different genotypes. (B) All genotypes had similar total cell number per blastocyst. (C) The percentage of ICM cells (OCT4 positive) in Mut embryos was significantly decreased and (D) the percentage of CDX2-positive TE cells in Mut embryos was significantly increased when compared with WT and Het littermates. Embryos evaluated in Fig. 3B, C and D: 9 WT, 26 Het, 10 Mut. (E) H4 acetylation (antibody recognizing H4K5 + K8 + K12 + K16) in blastocysts of different genotypes. Fluorescence intensity analysis of H4 acetylation in ICM cells (white outlines) showed no significant difference between genotypes when DAPI intensity (F) or OCT4 (G) was used as reference. Embryos evaluated in Fig. 3F and G: 5 WT, 14 Het, 6 Mut. Scale bars, 50 μ m. * P < 0.05.

OCT4 positive cell number, an increase in the percent of CDX2-positive cells is also evident (Fig. 3D). These results indicate that ICM and TE are both specified in the absence of *Mcrs1*, but that the ratio of cell allocation to each lineage is altered with only ~45% of the appropriate number of ICM cells present in mutants.

Considering this and the possible role of MCRS1 in histone H4 acetylation on multiple lysine residues (Cai *et al.* 2010), another batch of blastocysts (5 WT, 14 Het, 6 Mut) was evaluated for H4 acetylation levels, using an antibody that recognizes multiple H4ac residues (H4K5+K8+K12+K16). As shown in Fig. 3E and F, no significant difference was observed in the H4ac levels in ICM cells among different genotypes indicating there is no global loss of H4ac in MCRS1 mutants. Since we observed a reduction in ICM cell number (Fig. 3A and C), we also calculated H4ac intensity/OCT4 intensity to see if there is any correlation between H4ac and OCT4 expression in the absence of MCRS1. As shown in Fig. 3G, no significant difference was identified among different genotypes.

***Mcrs1* mutants have normal PE but defective EPI allocation**

To further explore the phenotype in *Mcrs1* mutant blastocysts, we investigated the fidelity of the second embryonic lineage decision, ICM segregation into epiblast (EPI) and primitive endoderm (PE). Blastocysts flushed from heterozygous intercrosses were assessed for the EPI marker NANOG and the PE marker SOX17 (Fig. 4A). From all 26 blastocysts genotyped (4 WT, 15 Het, 7 Mut), we found that Mut blastocysts contained a significantly reduced number and percentage of EPI cells (NANOG positive) when compared with WT and Het embryos (Fig. 4B and C). However, both the total number of PE cells per blastocyst (SOX17 positive, Fig. 4D) and the percentage of PE cells (Fig. 4E) were not significantly altered in *Mcrs1* mutants. Of the seven Mut blastocysts collected for this experiment, four had very few EPI cells, while other three (Fig. 4A, bottom row) contained no NANOG-positive cells within the ICM.

***Mcrs1* knockdown embryos phenocopy genetic-knockout mutants**

In order to establish a more efficient platform for studying the function of MCRS1 during development, we used RNA interference (RNAi) to knockdown (KD) *Mcrs1*. Two distinct *Mcrs1* siRNAs were individually microinjected into zygotes. Robust KD efficacy was confirmed at the early morula stage after microinjection with both siRNAs as evidenced by a loss of MCRS1 protein IF (Fig. 5A) and mRNA (Fig. 5B). Similar to the KO phenotype, *Mcrs1* KD did not affect blastocyst formation or morphology (Fig. 5C and G) but did lead to outgrowth failure, where all failed KD outgrowths

exhibited complete lack of morphologically evident ICM colony (Fig. 5G). Importantly, similar to the KO, KD with either siRNA did not change ratio of SOX17-positive PE cells (Fig. 5D), but did lead to a decrease in the ratio of NANOG-positive EPI cells (Fig. 5E), and concordantly an increase in the ratio of CDX2-positive TE cells (Fig. 5F), compared with control blastocysts (evaluated embryos: control=13, siRNA1=13, siRNA2=12). We speculated that a more severe KD phenotype might be achieved with extended culture time. As expected, when KD and control embryos were subjected to an additional 72-h outgrowth, a more severe phenotype was observed. Embryos that did not hatch during *in vitro* outgrowth had zero NANOG-positive cells in KD groups (0/21, siRNA1=10, siRNA2=11), while all embryos from the control group displayed robust NANOG-positive cells (11/11) (Fig. 6). For those KD embryos that did hatch during *in vitro* outgrowth, again, no NANOG-positive cells could be detected in KD outgrowths (0/20, siRNA1=10, siRNA2=10), whereas majority of the control outgrowths exhibited strong NANOG-positive cells (12/15) (Fig. 6). Furthermore, no obvious differences were noted in SOX17 or CDX2 expression in KD outgrowths (Fig. 6, additional examples shown in Supplementary Fig. 3). These results show that the phenotypes of *Mcrs1* KO can be fully recapitulated by microinjection of a single *Mcrs1* siRNA, resulting in severely reduced/no epiblast cells remaining in the absence of MCRS1 function.

Discussion

Lineage specification and subsequent cell differentiation is a complex and highly regulated process that occurs during the development of all multicellular eukaryotic organisms. Although the localization of specific transcription factors within ICM/TE and EPI/PE/TE lineages have been well studied during mammalian development, the upstream regulation of these critical factors is not fully understood (Paul & Knott 2014, Marcho *et al.* 2015, Cui & Mager 2018). Among the multiple signaling networks involved in early mammalian lineage specification, Hippo signaling has been shown to be involved in both TE (Strumpf *et al.* 2005, Yagi *et al.* 2007) and ICM (Wicklow *et al.* 2014) specification, while roles for Notch (Rayon *et al.* 2014) and ROCK signaling in TE fate acquisition have also been well supported (Kono *et al.* 2014, Negron-Perez *et al.* 2018). In addition, multiple factors are known to contribute to cell lineage segregation. For example, during mouse preimplantation, PRDM14 interacts with the methyltransferase CARM1 to promote methylation of arginine 26 of histone H3 (Burton *et al.* 2013). This interaction leads to an upregulation of NANOG and SOX2, biasing the progeny toward the ICM fate (Torres-Padilla *et al.* 2007). Explaining these observations, two newer studies have found that H3R26me potentiates

Figure 4 (A) IF of SOX17 (PE marker), NANOG (EPI marker), and CDX2 (TE marker) in blastocysts of different genotypes. (B and C) Both the number of EPI cells (NANOG positive) per blastocyst and percentage of EPI cells were significantly decreased in Mut embryos when compared with WT and Het embryos. (D and E) No significant difference in the number of PE cells (SOX17 positive) per blastocyst or percentage of PE cells was detected between genotypes. Scale bar, 50 μ m. * $P < 0.05$.

long-lived SOX2-DNA binding, ensuring access of SOX2 to its pluripotency-related targets while suppressing TE-specific genes, ultimately biasing blastomeres toward ICM (Goolam *et al.* 2016, White *et al.* 2016).

Recent single-cell expression profiling of human blastocyst-derived cells predicted that MCRS1 plays a role in EPI formation; however, its function during mammalian embryogenesis has not been studied *in*

Figure 5 (A and B) KD efficiency was confirmed at the early morula stage (2 days after microinjection) by both MCRS1 protein IF and RT-PCR. Scale bar, 50 μ m. (C, D, E and F) Lineage assessment in KD blastocysts showed that, compared with the Control group, *Mcrs1* KD did not alter the ratio of blastocyst cells with SOX17 (PE marker) or CDX2 (TE marker). However, as with KO of *Mcrs1*, the ratio of cells with NANOG (EPI marker) was decreased in each KD group. Scale bar, 50 μ m. Blastocysts were harvested at 4 days post microinjection and then fixed for immunofluorescence. (G) KD of *Mcrs1* by either siRNA did not affect blastocyst formation or morphology, but led to a significant failure of ICM outgrowth. Red and blue dashed lines indicate ICM outgrowth and trophoblast cells, respectively. Control: scrambled siRNA. *n*, number of embryos; * $P < 0.05$. Scale bars, 100 μ m.

Figure 6 Lineage assessment of control and KD embryos that were subjected to an additional 72 h of outgrowth (OG) culture. No NANOG-positive cells could be detected in any KD embryo, regardless of failure to hatch. The control group consistently displayed strong NANOG signal. Control: scrambled siRNA. In this experiment blastocysts were examined at 7 days post microinjection. Scale bars, 50 μm .

vivo (Durruthy-Durruthy *et al.* 2016). In the present study, we use KO and KD studies *in vivo* and *in vitro* to demonstrate the essential role of MCRS1 during mammalian embryogenesis. Our data show that *Mcrs1* mutant mouse embryos fail to implant and are unable to form ICM/epiblast colonies in outgrowth assays. Although previous studies using human cell lines have shown that *MCRS1* silencing leads to apoptosis (Hsu *et al.* 2012), we do not observe increased cell death in mutant embryos (Fig. 3A), suggesting that MCRS1 regulates cell allocation rather than cell survival *in vivo*. Furthermore, because MCRS1 is a subunit of the NSL complex which can acetylate nucleosomal histone H4 on multiple lysine residues (Cai *et al.* 2010), we examined if loss of MCRS1 led to a reduction in H4 acetylation. IF analysis revealed that KO of *Mcrs1* causes no significant global difference in H4 acetylation (H4K5 + K8 + K12 + K16) in the ICM of MCRS1 mutants (Fig. 3E). It is notable that the ENCODE database shows overlapping peaks of H4K8Ac and K4K91Ac at promoters of *OCT4* and *NANOG* but not *SOX17* in hESC ChIP-seq experiments (<https://www.encodeproject.org>). These findings are consistent with the hypothesis that MCRS1 does indeed facilitate H4Kac deposition and gene activity in the ICM/EPI and that a more sensitive locus-specific assay may be required to detect consequences of MCRS1 loss *in vivo*. siRNA KD of MCRS1 may allow for production of large numbers of embryos with which to perform such ChIP-seq experiments.

Our preliminary data show that knockout of *Mcrs1* did not alter cell lineage specification at E3.5 early blastocyst stage (Supplementary Fig. 4). We suspect this is due to maternally loaded MCRS1. It is also noteworthy that we used OCT4 as a definitive ICM marker (Fig. 3). However, it has been shown that loss of *Oct4* does not affect formation of ICM (Nichols *et al.* 1998), therefore, it is possible that there could be OCT4-negative ICM cells. Thorough analysis of all observed blastocysts revealed that all cells are either OCT4 or CDX2 positive and we did not detect any OCT4 negative ICM cells (Fig. 3). These results also highlight an important difference with other epiblast-failure phenotypes (TCF7L1 (Hoffman *et al.* 2013) and FOXD3 (Hanna *et al.* 2002)), in that *Mcrs1* KO embryos do specify ICM/TE normally but with far fewer ICM cells.

Our results clearly show a significant reduction of ICM cells, a reduction of NANOG-positive epiblast in E4.0 Muts and a complete loss of NANOG-positive cells in outgrowth assays in the absence of MCRS1 function. Importantly, TE and PE specification occur normally, highlighting the specific requirement of MCRS1 for epiblast specification or maintenance in murine blastocysts. It has been reported that a minimum of four NANOG-positive EPI cells are needed at the blastocyst stage for normal embryo development (Morris *et al.* 2012). Consistent with this report, our data show that all WTs (4/4) and majority of Hets (13/15) reached and

surpassed this threshold, while only one of seven *Mcrs1* mutants obtained a minimal number of four NANOG-positive cells (1/7, Fig. 4B). It is noteworthy that MCRS1 protein shows ICM-enriched but not ICM-exclusive expression/localization pattern in mouse blastocysts, which is consistent with immunostaining of MCRS1 in human blastocysts (Durruthy-Durruthy *et al.* 2016). Therefore, we hypothesize that MCRS1 has multiple functions during embryo development. Previous studies have also confirmed that MCRS1 can be detected at different regions of the cell to perform different roles, such as in nucleolus to regulate rRNA transcription (Ren *et al.* 1998), in the nucleus to control gene transcription (Du *et al.* 2006, Andersen *et al.* 2010), on the centrosome to modulate mitosis and cell cycle transition (Hirohashi *et al.* 2006), as well as in the cytoplasm to regulate mRNA translation (Davidovic *et al.* 2006). While MCRS1 may not directly regulate global histone acetylation, we hypothesize that MCRS1 may directly regulate histone acetylation at transcription factors loci that are essential for EPI specification and maintenance. Documented MCRS1 function during induction of naive pluripotency in human ESCs (Durruthy-Durruthy *et al.* 2016) and its regulation of stem cell marker ITGA6 in cancer cells (Liu *et al.* 2014) support this hypothesis. Together, our study demonstrates that MCRS1 is essential for embryo survival by promoting the epiblast lineage during early murine embryogenesis *in vivo* and *in vitro*.

Supplementary materials

This is linked to the online version of the paper at <https://doi.org/10.1530/REP-19-0334>.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This work was supported by R01HD083311 to J M and faculty start-up fund to W C.

Author contribution statement

W C designed the experiments, performed the majority of the experiments, analyzed the data and wrote the manuscript; A C conducted gastrulation embryo imaging and genotyping; Y W participated in preimplantation embryo immunofluorescence and outgrowth assays; Y T contributed to mouse maintenance and genotyping; Y L and K D T participated in critical discussion and edited the manuscript; J M participated in experimental design, embryo dissection, data analysis and edited the manuscript. All authors reviewed the manuscript.

Acknowledgements

The authors thank the Knockout Mouse Phenotyping Program (KOMP2) and The Jackson Laboratory for providing *Mcrs1*-knockout allele. They also thank Morgane Golan for assistance in genotyping. The confocal microscopy data were gathered in the Light Microscopy Facility and Nikon Center of Excellence at the Institute for Applied Life Sciences, UMass Amherst with support from the Massachusetts Life Sciences Center.

References

- An Q, Peng W, Cheng Y, Lu Z, Zhou C, Zhang Y & Su J 2019 Melatonin supplementation during in vitro maturation of oocyte enhances subsequent development of bovine cloned embryos. *Journal of Cellular Physiology* **234** 17370–17381. (<https://doi.org/10.1002/jcp.28357>)
- Andersen DS, Raja SJ, Colombani J, Shaw RL, Langton PF, Akhtar A & Tapon N 2010 Drosophila MCRS2 associates with RNA polymerase II complexes to regulate transcription. *Molecular and Cellular Biology* **30** 4744–4755. (<https://doi.org/10.1128/MCB.01586-09>)
- Arny M, Nachtigall L & Quagliarello J 1987 The effect of preimplantation culture conditions on murine embryo implantation and fetal development. *Fertility and Sterility* **48** 861–865. ([https://doi.org/10.1016/S0015-0282\(16\)59545-4](https://doi.org/10.1016/S0015-0282(16)59545-4))
- Benavides M, Chow-Tsang LF, Zhang J & Zhong H 2013 The novel interaction between microsphere protein Msp58 and ubiquitin E3 ligase EDD regulates cell cycle progression. *Biochimica et Biophysica Acta* **1833** 21–32. (<https://doi.org/10.1016/j.bbamcr.2012.10.007>)
- Burton A, Muller J, Tu S, Padilla-Longoria P, Guccione E & Torres-Padilla ME 2013 Single-cell profiling of epigenetic modifiers identifies PRDM14 as an inducer of cell fate in the mammalian embryo *Cell Reports* **5** 687–701. (<https://doi.org/10.1016/j.celrep.2013.09.044>)
- Cai Y, Jin J, Swanson SK, Cole MD, Choi SH, Florens L, Washburn MP, Conway JW & Conaway RC 2010 Subunit composition and substrate specificity of a MOF-containing histone acetyltransferase distinct from the male-specific lethal (MSL) complex. *Journal of Biological Chemistry* **285** 4268–4272. (<https://doi.org/10.1074/jbc.C109.087981>)
- Cao Z, Carey TS, Ganguly A, Wilson CA, Paul S & Knott JG 2015 Transcription factor AP-2gamma induces early Cdx2 expression and represses HIPPO signaling to specify the trophectoderm lineage. *Development* **142** 1606–1615. (<https://doi.org/10.1242/dev.120238>)
- Cui W & Mager J 2018 Transcriptional regulation and genes involved in first lineage specification during preimplantation development. *Advances in Anatomy, Embryology, and Cell Biology* **229** 31–46. (https://doi.org/10.1007/978-3-319-63187-5_4)
- Cui W, Dai X, Marcho C, Han Z, Zhang K, Tremblay KD & Mager J 2016 Towards functional annotation of the preimplantation transcriptome: an RNAi screen in mammalian embryos. *Scientific Reports* **6** 37396. (<https://doi.org/10.1038/srep37396>)
- Cui W, Marcho C, Wang Y, Degani R, Golan M, Tremblay KD, Rivera-Perez J & Mager J 2018 Med20 is essential for early embryogenesis and regulates Nanog expression. *Reproduction* **157** 215–222. (<https://doi.org/10.1530/REP-18-0508>)
- Davidovic L, Bechara E, Gravel M, Jaglin XH, Tremblay S, Sik A, Bardoni B & Khandjian EW 2006 The nuclear microsphere protein 58 is a novel RNA-binding protein that interacts with fragile X mental retardation protein in polyribosomal mRNPs from neurons. *Human Molecular Genetics* **15** 1525–1538. (<https://doi.org/10.1093/hmg/ddl074>)
- Du X, Wang Q, Hirohashi Y & Greene MI 2006 DIPA, which can localize to the centrosome, associates with p78/MCRS1/MSP58 and acts as a repressor of gene transcription. *Experimental and Molecular Pathology* **81** 184–190. (<https://doi.org/10.1016/j.yexmp.2006.07.008>)
- Durruthy-Durruthy J, Wossidlo M, Pai S, Takahashi Y, Kang G, Omberg L, Chen B, Nakauchi H, Reijo Pera R & Sebastiano V 2016 Spatiotemporal reconstruction of the human blastocyst by single-cell gene-expression analysis informs induction of naive pluripotency. *Developmental Cell* **38** 100–115. (<https://doi.org/10.1016/j.devcel.2016.06.014>)
- Fawal MA, Brandt M & Djoudier N 2015 MCRS1 binds and couples Rheb to amino acid-dependent mTORC1 activation. *Developmental Cell* **33** 67–81. (<https://doi.org/10.1016/j.devcel.2015.02.010>)
- Goolam M, Scialdone A, Graham SJL, Macaulay IC, Jedrusik A, Hupalowska A, Voet T, Marioni JC & Zernicka-Goetz M 2016 Heterogeneity in Oct4 and Sox2 targets biases cell fate in 4-cell mouse embryos. *Cell* **165** 61–74. (<https://doi.org/10.1016/j.cell.2016.01.047>)
- Hanna LA, Foreman RK, Tarasenko IA, Kessler DS & Labosky PA 2002 Requirement for Foxd3 in maintaining pluripotent cells of the early mouse embryo. *Genes and Development* **16** 2650–2661. (<https://doi.org/10.1101/gad.1020502>)
- Hirohashi Y, Wang Q, Liu Q, Du X, Zhang H, Sato N & Greene MI 2006 p78/MCRS1 forms a complex with centrosomal protein Nde1 and is essential for cell viability. *Oncogene* **25** 4937–4946. (<https://doi.org/10.1038/sj.onc.1209500>)
- Hoffman JA, Wu CI & Merrill BJ 2013 Tcf7l1 prepares epiblast cells in the gastrulating mouse embryo for lineage specification. *Development* **140** 1665–1675. (<https://doi.org/10.1242/dev.087387>)
- Houliston E & Maro B 1989 Posttranslational modification of distinct microtubule subpopulations during cell polarization and differentiation in the mouse preimplantation embryo. *Journal of Cell Biology* **108** 543–551. (<https://doi.org/10.1083/jcb.108.2.543>)
- Hsu CC, Lee YC, Yeh SH, Chen CH, Wu CC, Wang TY, Chen YN, Hung LY, Liu YW, Chen HK et al. 2012 58-kDa microsphere protein (MSP58) is novel Brahma-related gene 1 (BRG1)-associated protein that modulates p53/p21 senescence pathway. *Journal of Biological Chemistry* **287** 22533–22548. (<https://doi.org/10.1074/jbc.M111.335331>)
- Jin J, Cai Y, Yao T, Gottschalk AJ, Florens L, Swanson SK, Gutierrez JL, Coleman MK, Workman JL, Mushegian A et al. 2005 A mammalian chromatin remodeling complex with similarities to the yeast INO80 complex. *Journal of Biological Chemistry* **280** 41207–41212. (<https://doi.org/10.1074/jbc.M509128200>)
- Kono K, Tamashiro DA & Alarcon VB 2014 Inhibition of Rho-ROCK signaling enhances ICM and suppresses TE characteristics through activation of Hippo signaling in the mouse blastocyst. *Developmental Biology* **394** 142–155. (<https://doi.org/10.1016/j.ydbio.2014.06.023>)
- Latham KE, Solter D & Schultz RM 1991 Activation of a two-cell stage-specific gene following transfer of heterologous nuclei into enucleated mouse embryos. *Molecular Reproduction and Development* **30** 182–186. (<https://doi.org/10.1002/mrd.1080300303>)
- Liu MX, Zhou KC & Cao Y 2014 MCRS1 overexpression, which is specifically inhibited by miR-129*, promotes the epithelial-mesenchymal transition and metastasis in non-small cell lung cancer. *Molecular Cancer* **13** 245. (<https://doi.org/10.1186/1476-4598-13-245>)
- Liu Y, Wu F, Zhang L, Wu X, Li D, Xin J, Xie J, Kong F, Wang W, Wu Q et al. 2018 Transcriptional defects and reprogramming barriers in somatic cell nuclear reprogramming as revealed by single-embryo RNA sequencing. *BMC Genomics* **19** 734. (<https://doi.org/10.1186/s12864-018-5091-1>)
- Marcho C, Cui W & Mager J 2015 Epigenetic dynamics during preimplantation development. *Reproduction* **150** R109–R120. (<https://doi.org/10.1530/REP-15-0180>)
- Morris SA, Guo Y & Zernicka-Goetz M 2012 Developmental plasticity is bound by pluripotency and the Fgf and Wnt signaling pathways. *Cell Reports* **2** 756–765. (<https://doi.org/10.1016/j.celrep.2012.08.029>)
- Negron-Perez VM, Rodrigues LT, Mingoti GZ & Hansen PJ 2018 Role of ROCK signaling in formation of the trophectoderm of the bovine preimplantation embryo. *Molecular Reproduction and Development* **85** 374–375. (<https://doi.org/10.1002/mrd.22976>)
- Nichols J, Zevnik B, Anastasiadis K, Niwa H, Klewe-Nebenius D, Chambers I, Scholer H & Smith A 1998 Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. *Cell* **95** 379–391. ([https://doi.org/10.1016/S0092-8674\(00\)81769-9](https://doi.org/10.1016/S0092-8674(00)81769-9))
- Niwa H, Toyooka Y, Shimosato D, Strumpf D, Takahashi K, Yagi R & Rossant J 2005 Interaction between Oct3/4 and Cdx2 determines trophectoderm differentiation. *Cell* **123** 917–929. (<https://doi.org/10.1016/j.cell.2005.08.040>)
- Paul S & Knott JG 2014 Epigenetic control of cell fate in mouse blastocysts: the role of covalent histone modifications and chromatin remodeling. *Molecular Reproduction and Development* **81** 171–182. (<https://doi.org/10.1002/mrd.22219>)
- Rayon T, Menchero S, Nieto A, Xenopoulos P, Crespo M, Cockburn K, Cañon S, Sasaki H, Hadjantonakis AK, de la Pompa JL et al. 2014 Notch

- and hippo converge on Cdx2 to specify the trophectoderm lineage in the mouse blastocyst. *Developmental Cell* **30** 410–422. (<https://doi.org/10.1016/j.devcel.2014.06.019>)
- Ren Y, Busch RK, Perlaky L & Busch H 1998 The 58-kDa microspherule protein (MSP58), a nucleolar protein, interacts with nucleolar protein p120. *European Journal of Biochemistry* **253** 734–742. (<https://doi.org/10.1046/j.1432-1327.1998.2530734.x>)
- Schneider CA, Rasband WS & Eliceiri KW 2012 NIH Image to ImageJ: 25 years of image analysis. *Nature Methods* **9** 671–675. (<https://doi.org/10.1038/nmeth.2089>)
- Strumpf D, Mao CA, Yamanaka Y, Ralston A, Chawengsaksophak K, Beck F & Rossant J 2005 Cdx2 is required for correct cell fate specification and differentiation of trophectoderm in the mouse blastocyst. *Development* **132** 2093–2102. (<https://doi.org/10.1242/dev.01801>)
- Sutherland AE & Calarco-Gillam PG 1983 Analysis of compaction in the preimplantation mouse embryo. *Developmental Biology* **100** 328–338. ([https://doi.org/10.1016/0012-1606\(83\)90227-0](https://doi.org/10.1016/0012-1606(83)90227-0))
- Tompers DM, Foreman RK, Wang Q, Kumanova M & Labosky PA 2005 Foxd3 is required in the trophoblast progenitor cell lineage of the mouse embryo. *Developmental Biology* **285** 126–137. (<https://doi.org/10.1016/j.ydbio.2005.06.008>)
- Torres-Padilla ME, Parfitt DE, Kouzarides T & Zernicka-Goetz M 2007 Histone arginine methylation regulates pluripotency in the early mouse embryo. *Nature* **445** 214–218. (<https://doi.org/10.1038/nature05458>)
- Tremblay KD, Hoodless PA, Bikoff EK & Robertson EJ 2000 Formation of the definitive endoderm in mouse is a Smad2-dependent process. *Development* **127** 3079–3090.
- White MD, Angiolini JF, Alvarez YD, Kaur G, Zhao ZW, Mocskos E, Bruno L, Bissiere S, Levi V & Plachta N 2016 Long-lived binding of Sox2 to DNA predicts cell fate in the four-cell mouse embryo. *Cell* **165** 75–87. (<https://doi.org/10.1016/j.cell.2016.02.032>)
- Wicklow E, Blij S, Frum T, Hirate Y, Lang RA, Sasaki H & Ralston A 2014 HIPPO pathway members restrict SOX2 to the inner cell mass where it promotes ICM fates in the mouse blastocyst. *PLoS Genetics* **10** e1004618. (<https://doi.org/10.1371/journal.pgen.1004618>)
- Yagi R, Kohn MJ, Karavanova I, Kaneko KJ, Vullhorst D, DePamphilis ML & Buonanno A 2007 Transcription factor TEAD4 specifies the trophectoderm lineage at the beginning of mammalian development. *Development* **134** 3827–3836. (<https://doi.org/10.1242/dev.010223>)

Received 24 July 2019

First decision 3 September 2019

Revised manuscript received 3 October 2019

Accepted 29 October 2019